Lately, studies have demonstrated that targeting TPX2 in PCa reduced the rate of chromosome mis-segregation and, consequently, TPX2 is considered as a candidate biomarker for therapy [68]. The gene discussed is TPX2; the disease is posterior cortical atrophy.